DMAC

8.2602.99%
DJ

Daniel J. O'Connor

Independent Director

Mr. Daniel J. O'Connor, J.D. also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He served as President, CEO and Director of Ambrx Biopharma Inc. since November 2022 until 2024. He had been Chairman of the Board and Chief Executive Officer at Larkspur Health Acquisition Corp. since March 17, 2021. He served as Chief Executive Officer of OncoSec Medical, Inc. since November 2017 until June 25, 2021 and served as its President since May 2, 2018. He also served as Director at OncoSec Medical Incorporated since September 2017 until June 25, 2021. Mr. O'Connor served as President and Chief Executive Officer of Advaxis Immunotherapies since August 19, 2013 to July 3, 2017. Prior to that, Mr. O’Connor was Senior Vice President and General Counsel for Bracco Diagnostics, a diagnostic imaging company, from 2008 until 2012; Senior Vice President, General Counsel and Secretary for ImClone Systems, a biopharmaceutical company, from 2002 until 2008; and General Counsel at PharmaNet (formerly inVentiv Clinical Health, today Syneos Health), a clinical research organization, from 1998 until 2001. He was also instrumental in establishing major Partnerships with companies including Amgen Inc. Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, Advaxis advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda(R) and Opdivo(R). Mr. O’Connor was also a Member of the Board of Trustees of BioNJ from 2015 to 2021 and previously served as its Vice Chairman. He has worked as executive and leadership in all aspects of the biopharmaceutical industry. He had been an Independent Director of Seelos Therapeutics Inc since January 24, 2019 until May 02, 2024. Mr. O'Connor serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988. Additionally, he has led numerous life science licensing transactions and drug development collaborations with major pharmaceutical companies. In October 2017, Mr. O’Connor was appointed to the New Jersey Biotechnology Task Force by its Governor. He was commissioned as a Lieutenant in the U.S. Marines, attaining the rank of Captain and was deployed to Saudi Arabia for Operation Desert Shield. Prior to his career in drug development, Mr. O’Connor was a former criminal prosecutor in Somerset County, New Jersey. A 1995 graduate of the Penn State University's Dickinson School of Law in Carlisle, Pennsylvania. He earned a J.D. from the Dickinson School of Law of Pennsylvania State University and a B.A. from Boston University.

Positions